Revisiting dexamethasone use in the pediatric emergency department.
Journal
Current opinion in pediatrics
ISSN: 1531-698X
Titre abrégé: Curr Opin Pediatr
Pays: United States
ID NLM: 9000850
Informations de publication
Date de publication:
01 Jun 2024
01 Jun 2024
Historique:
medline:
24
4
2024
pubmed:
24
4
2024
entrez:
24
4
2024
Statut:
ppublish
Résumé
Dexamethasone is an essential treatment for common pediatric inflammatory, airway, and respiratory conditions. We aim to provide up-to-date recommendations for treatment of anaphylaxis, croup, coronavirus disease, multisystem inflammatory syndrome in children, and asthma with dexamethasone for use in the pediatric emergency department. Literature largely continues to support the use of dexamethasone in most of the above conditions, however, recommendations for dosing and duration are evolving. The findings discussed in this review will enable pediatric emergency medicine providers to use dexamethasone effectively as treatment of common pediatric conditions and minimize the occurrence of side-effects caused by gratuitous corticosteroid use.
Identifiants
pubmed: 38655807
doi: 10.1097/MOP.0000000000001351
pii: 00008480-202406000-00003
doi:
Substances chimiques
Dexamethasone
7S5I7G3JQL
Glucocorticoids
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
251-255Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Corneli HM, Holubkov R, Nelson KA, et al. A Multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. N Engl J Med 2007; 357:331–339.
Hayward GN, Hay AD, Moore MV, et al. Effect of oral dexamethasone without immediate antibiotics vs placebo on acute sore throat in adults: a randomized clinical trial. JAMA 2017; 317:1535.
Bulloch B, Kabani A, Tenenbein M. Oral dexamethasone for the treatment of pain in children with acute pharyngitis: a randomized, double-blind, placebo-controlled trial. Ann Emerg Med 2003; 41:601–608.
Dribin TE, Neuman MI, Schnadower D, et al. Trends and variation in pediatric anaphylaxis care from 2016 to 2022. J Allergy Clin Immunol Pract 2023; 11:1184–1189.
Gaffney LK, Porter J, Gerling M, et al. Safely reducing hospitalizations for anaphylaxis in children through an evidence-based guideline. Pediatrics 2022; 149:e2020045831.
Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med 2020; 8:267–276.
The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 2021; 384:693–704.
Asif A, Tayyab A, Qazi S, et al. Comparison between single-dose oral prednione and oral dexamethasone in the treatment of croup: a randomized-controlled trial. Ann Med Surg 2023; 85:1379–1384.
Aregbesola A, Tam CM, Kothari A, et al. Glucocorticoids for croup in children. Cochrane Acute Respiratory Infections Group. Cochrane Database Syst Rev. 2023; [cited 2024 Jan 16]. Available at: http://doi.wiley.com/10.1002/14651858.CD001955.pub5.
Siebert JN, Salomon C, Taddeo I, et al. Outdoor cold air versus room temperature exposure for croup symptoms: a randomized controlled trial. Pediatrics 2023; 152:e2023061365.
Jiang W, Hall M, Berry J. Comparative effectiveness of dexamethasone versus prednisone in children hospitalized with acute croup. U.S. National Library of Medicine; 2022 [cited 2024 Jan 17]. Available at: https://pubmed.ncbi.nlm.nih.gov/36106471/.
Matthay MA, Zemans RL, Zimmerman GA, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006; 354:1671–1684.
Meduri GU, Golden E, Freire AX, et al. Methylprednisolone infusion in early severe ARDS. Chest 2007; 131:954–963.
Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX Randomized Clinical Trial. JAMA 2020; 324:1307–1316.
Emeriaud G, López-Fernández YM, Iyer NP, et al. Executive summary of the second international guidelines for the diagnosis and management of pediatric acute respiratory distress syndrome (PALICC-2). Pediatr Crit Care Med 2023; 24:143–168.
Boast A, Curtis N, Holschier J, et al. An approach to the treatment of children with COVID-19. Pediatr Infect Dis J 2022; 41:654–662.
Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020; 395:1607–1608.
Belhadjer Z, Méot M, Bajolle F, et al. Acute heart failure in multisystem inflammatory syndrome in children in the context of global SARS-CoV-2 pandemic. Circulation 2020; 142:429–436.
Son MBF, Murray N, Friedman K, et al. Multisystem inflammatory syndrome in children — initial therapy and outcomes. N Engl J Med 2021; 385:23–34.
McArdle AJ, Vito O, Patel H, et al. Treatment of multisystem inflammatory syndrome in children. N Engl J Med 2021; 385:11–22.
Cai KJ, Su SQ, Wang YG, Zeng YM. Dexamethasone versus prednisone or prednisolone for acute pediatric asthma exacerbations in the emergency department: a meta-analysis. Pediatr Emerg Care 2021; 37:e1139–e1144.
Rowe BH, Bretzlaff J, Bourdon C, et al. Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev 2001; (1):CD002178.
Navanandan N, Moss A, Tanverdi M, et al. Corticosteroid choice and clinical outcomes for asthma exacerbations in the primary care setting. J Asthma 2022; 59:333–341.
Normansell R, Kew KM, Mansour G. Different oral corticosteroid regimens for acute asthma. Cochrane Airways Group. Cochrane Database Syst Rev. 2016. Available at: http://doi.wiley.com/10.1002/14651858.CD011801.pub2.
Cronin JJ, McCoy S, Kennedy U, et al. A randomized trial of single-dose oral dexamethasone versus multidose prednisolone for acute exacerbations of asthma in children who attend the emergency department. Ann Emerg Med 2016; 67:593–601. e3.
Sellers AR, Roddy MR, Darville KK, et al. Dexamethasone for pediatric critical asthma: a multicenter descriptive study. J Intensive Care Med 2022; 37:1520–1527.
Doymaz S, Ahmed YE, Francois D, et al. Methylprednisolone, dexamethasone or hydrocortisone for acute severe pediatric asthma: does it matter? J Asthma 2022; 59:590–596.
Roddy MR, Sellers AR, Darville KK, et al. Dexamethasone versus methylprednisolone for critical asthma: a single center, open-label, parallel-group clinical trial. Pediatr Pulmonol 2023; 58:1719–1727.
Martin M, Penque M, Wrotniak BH, et al. Single-dose dexamethasone is not inferior to 2 doses in mild to moderate pediatric asthma exacerbations in the emergency department. Pediatr Emerg Care 2022; 38:e1285–e1290.
Dahan E, El Ghazal N, Nakanishi H, et al. Dexamethasone versus prednisone/prednisolone in the management of pediatric patients with acute asthmatic exacerbations: a systematic review and meta-analysis. J Asthma 2023; 60:1481–1492.